Intellia Therapeutics secures $400 million senior secured term loan facility with OrbiMed
NTLA•Intellia signs $400 million term loan facility with OrbiMed
Intellia Therapeutics signed a $400 million non-dilutive senior secured term loan facility with OrbiMed.
- $75 million funded at closing.
- Up to $225 million available in five tranches tied mainly to lonvo-z milestones.
- An additional $100 million available during the five-year term, subject to mutual agreement.
The facility is aimed at funding a planned U.S. approval and commercial launch of lonvo-z for hereditary angioedema.
